Clinical Research
News & Careers
Search the Site
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login           Employers:  Register | Login   

By Industry | By Industry Segment | By Services and Suppliers | By Location | Profile Search
 Company Profile


Repros Therapeutics Inc. 

2408 Timberloch Place
Suite B-7
The Woodlands  Texas  77380  U.S.A.
Phone: 281-719-3400 Fax: 281-719-3446


 Company News
Repros Therapeutics Inc. (RPRX) Reports Third Quarter 2014 Financial Results 11/10/2014 8:02:14 AM
Repros Therapeutics Inc. (RPRX) Holds Constructive Meeting With FDA Regarding Androxal® NDA Filing 11/7/2014 7:36:52 AM
Repros Therapeutics Inc. (RPRX) To Webcast Investor And Analyst Day On October 31st 10/28/2014 7:06:42 AM
Repros Therapeutics Inc. (RPRX) Release: Results From Long-Term Study Of Androxal® Exhibit Positive Safety Profile 10/22/2014 7:00:11 AM
Repros Therapeutics Inc. (RPRX) Shares Tank On Drug Application Setback 10/17/2014 7:15:39 AM
Repros Therapeutics Inc. (RPRX) Release: Androxal® Second Pivotal Study Achieves Superiority In Top Line Analysis For Both Co-Primary Endpoints Versus Marketed Topical Gel In The Treatment Of Secondary Hypogonadism 9/26/2014 7:16:45 AM
FDA Schedules Type B Pre-NDA Meeting With Repros Therapeutics Inc. (RPRX) 9/25/2014 2:24:54 PM
Repros Therapeutics Inc. (RPRX) Gives Update On Androxal® With Respect To Recent FDA Advisory Panel Outcome And Announces Upcoming Presentation At Biocentury 9/22/2014 8:11:03 AM
Repros Therapeutics Inc. (RPRX)'s Testosterone Drug Found Superior To AbbVie (ABBV)'s Androgel In Study 8/28/2014 6:09:13 AM
Repros Therapeutics Inc. (RPRX) Reports Second Quarter 2014 Financial Results 8/11/2014 7:51:03 AM